2025-2026 Flu Assessment: Severity, Symptoms, and Emergence of Subclade K

Abstract

The 2025-2026 influenza season in the United States represents a significant epidemiological event characterized by the rapid and early acceleration of Influenza A(H3N2) activity. As of late December 2025 (CDC Surveillance Week 51), the nation has witnessed a sharp vertical trajectory in case counts, outpatient visits for influenza-like illness (ILI), and hospital admissions, driven almost exclusively by the emergence of the subclade K (J.2.4.1) variant. This report provides an exhaustive analysis of the current season, synthesizing national surveillance data which estimates 7.5 million illnesses and 81,000 hospitalizations to date. We explore the molecular evolution of the subclade K variant, detailing the specific amino acid substitutions in the hemagglutinin protein (e.g., T135K, K189R) that have facilitated partial immune escape and necessitated a re-evaluation of vaccine effectiveness. Furthermore, this article examines the clinical discourse surrounding the so-called "Super Flu," analyzing severity metrics, pediatric mortality, and the critical role of secondary bacterial infections in shaping patient outcomes. Despite a documented antigenic mismatch with the Northern Hemisphere vaccine reference strain, real-world data suggests preserved effectiveness against severe disease, particularly in pediatric populations. This comprehensive review aims to provide a granular understanding of the ongoing viral dynamics to inform clinical practice and public health strategy.

Introduction

The 2025-2026 Season Context

The cyclical nature of seasonal influenza is a persistent challenge to public health, yet the 2025-2026 season has distinguished itself through an unusually aggressive onset and a distinct virological profile. Following the respiratory virus seasons of the early 2020s, which were often complicated by the synchronous circulation of SARS-CoV-2 and Respiratory Syncytial Virus (RSV), the current season is being defined primarily by the resurgence of Influenza A(H3N2).¹ Historically, seasons dominated by the H3N2 subtype are associated with higher burdens of morbidity and mortality, particularly among the elderly and frail, due to the virus's rapid mutation rate and the waning of H3-specific immunity in older populations.

By mid-December 2025, the United States had entered a phase of sustained and elevated viral activity. The Centers for Disease Control and Prevention (CDC) reported that key activity indicators—including test positivity and hospitalization rates—were increasing vertically, signaling the start of the season in earnest.¹ This surge was not unexpected; early warning signals from the Southern Hemisphere, specifically Australia and New Zealand, had indicated a robust flu season driven by a drifted viral strain.³ However, the velocity with which the virus has established dominance in the United States has placed immediate pressure on healthcare systems, with cumulative hospitalizations reaching their third-highest point for this time of year since the 2010-2011 season.⁵

Global Precursors: The Southern Hemisphere Signal

The interconnected nature of global epidemiology necessitates looking beyond national borders to understand local outbreaks. The trajectory of the 2025-2026 U.S. season was prefigured by events in the Southern Hemisphere during their winter (June–August 2025). Surveillance data from Australia revealed a prolonged influenza season, initially driven by Influenza A(H1N1) but overtaken in its later stages by a novel H3N2 variant.³

This variant, identified as subclade K, demonstrated a transmission advantage that allowed it to surge even as the overall flu season was waning. Following its expansion in the Southern Hemisphere, the variant seeded outbreaks in the Northern Hemisphere, appearing first in significant numbers in Japan and the United Kingdom before becoming the dominant strain in North America.⁶ The synchronization of these outbreaks suggests a variant with high intrinsic fitness and transmissibility, capable of exploiting gaps in global population immunity. The U.S. experience is thus a continuation of a global wave, characterized by the replacement of the previously dominant J.2 subclade with the evolved K lineage.

Molecular Virology of Influenza A(H3N2) Subclade K

Phylogenetic Origins and Taxonomy

The influenza virus is an RNA virus prone to high rates of mutation, a process known as antigenic drift. The H3N2 subtype, in particular, exhibits a "ladder-like" phylogeny where a single dominant trunk lineage continually spawns new side branches that either persist or perish based on their ability to evade host immunity. The virus driving the 2025-2026 epidemic belongs to the 3C.2a1b.2a.2 subclade, specifically a further differentiated lineage designated as J.2.4.1.⁸

Scientific and public health bodies have adopted the shorthand nomenclature "subclade K" to refer to this J.2.4.1 lineage.¹⁰ Phylogenetic analysis indicates that subclade K diverged from the clade 3C.2a1b.2a.2 parent lineage through the acquisition of a specific set of mutations. By late 2025, sequencing data from U.S. public health laboratories showed a near-total replacement event: among Influenza A(H3N2) viruses genetically characterized since late September, approximately 89.5% to 89.8% belonged to subclade K.¹ This dominance highlights the variant's evolutionary success in outcompeting the H1N1 strains and other H3N2 lineages that were co-circulating earlier in the year.

Genomic Architecture: The J.2.4.1 Lineage

The biological basis for subclade K's dominance lies in its specific genomic architecture, particularly mutations within the hemagglutinin (HA) gene. The HA protein is the primary antigen recognized by neutralizing antibodies; therefore, changes in this protein are critical for immune evasion.

Sequence analysis has identified a constellation of amino acid substitutions that define the K subclade. Key substitutions compared to the J.2 reference strains include:

• T135K: A threonine-to-lysine mutation at position 135.

• K189R: A lysine-to-arginine mutation at position 189.⁹

In addition to these defining mutations, subclade K viruses often carry a suite of other changes, including K2N, S144N, N158D, I160K, Q173R, T328A, and S378N.⁹ The accumulation of these mutations represents a significant drift from the ancestral strains circulating in previous years.

Antigenic Drift and Structural Analysis

The functional impact of these mutations is profound. The mutation at position 135 (T135K) is of particular interest to virologists because it results in the loss of an N-linked glycosylation site.¹³ Glycosylation involves the attachment of sugar molecules to the viral surface proteins, which can act as a shield, masking antigenic sites from antibody recognition. Paradoxically, the loss of a glycosylation site can sometimes expose new epitopes, but in the context of H3N2 evolution, changes at site 135 often alter the shape of the receptor-binding domain sufficiently to reduce antibody binding affinity.

The S144N mutation occurs in Antigenic Site A, a region of the HA protein that is a major target for neutralizing antibodies. Mutations in this region are historically associated with significant antigenic drift events that necessitate vaccine updates.¹²

The cumulative effect of these mutations is an "antigenic mismatch." Laboratory studies using ferret antisera—the gold standard for assessing how well antibodies raised against one virus can recognize another—have shown reduced reactivity between antibodies generated by the 2025-2026 Northern Hemisphere vaccine strains (based on subclade J.2) and the circulating subclade K viruses.¹ This reduction in cross-reactivity provides the mechanistic explanation for the high case counts: vaccination or prior infection provides less sterilizing immunity against subclade K, allowing the virus to establish infection more easily in exposed individuals.

Epidemiological Surveillance and Transmission Dynamics

National Trends: The Vertical Trajectory

The 2025-2026 epidemiological curve in the United States follows a "vertical" ascent pattern, indicative of a highly transmissible pathogen moving through a susceptible population. Through October and November 2025, influenza activity remained relatively low, hovering near inter-seasonal baselines.¹⁴ However, the onset of December marked a dramatic inflection point.

Table 1: Weekly Comparison of Key Surveillance Indicators.¹

The leap in test positivity from 14.8% to 25.6% in a single week is a critical indicator of viral acceleration.¹ A positivity rate exceeding 25% is significantly high for early winter, suggesting that the effective reproduction number (R_t) is well above 1. Furthermore, the volume of positive specimens more than doubled between Week 50 and Week 51, confirming that the rise in positivity is not an artifact of decreased testing but a genuine surge in viral prevalence.

Cumulative estimates from the CDC through Week 51 place the burden of disease at approximately 7,500,000 illnesses, 81,000 hospitalizations, and 3,100 deaths.² These figures represent a rapid accumulation of morbidity, outpacing many recent pre-pandemic seasons.

Regional Heterogeneity and Geographic Diffusion

The transmission of influenza across the continental United States rarely occurs uniformly. The 2025-2026 season has exhibited pronounced regional heterogeneity, with the viral epicenter located in the Mountain West and moving rapidly toward the East Coast.

Data from the Department of Health and Human Services (HHS) regions reveals striking disparities in viral activity:

• Region 8 (Mountain West): This region, comprising Colorado, Montana, North Dakota, South Dakota, Utah, and Wyoming, reported the highest intensity in the nation, with a percent positivity of 34.9% in Week 51.¹ This extremely high positivity rate suggests that the epidemic peaked earlier in these states, potentially driven by colder weather patterns forcing indoor congregation earlier in the season.

• Region 9 (Pacific West): In contrast, Region 9 (Arizona, California, Hawaii, Nevada) reported the lowest positivity at 10.8%.⁵ While still elevated, this lower rate indicates that the peak in the West Coast lag behind the interior of the country.

• Region 4 (Southeast): The Southeast is experiencing a severe acceleration. Georgia, for instance, reported a significant spike in mortality, with seven influenza-associated deaths occurring in the single week between December 20 and December 27.¹⁵ This brought the state's seasonal death toll to 29, a stark contrast to the zero deaths reported at the same time the previous year.¹⁵

• Northeast (Regions 1 & 2): New York reported 71,000 flu cases in a single week in December, the highest weekly figure recorded since 2004.¹⁶ This historic high highlights the sheer transmissibility of the subclade K variant in densely populated urban environments.

This geographic staggering—where the Mountain regions burn hot while the coasts accelerate—suggests that the national "peak" may be prolonged as the virus migrates through different communities.

Hospitalization and Morbidity Metrics

The translational impact of these high infection rates is visible in hospitalization data. The Influenza Hospitalization Surveillance Network (FluSurv-NET) reported a cumulative hospitalization rate of 18.2 per 100,000 population by Week 51.⁵ This is the third-highest cumulative rate observed at this point in the season since 2010, trailing only the exceptionally severe 2022-2023 and 2023-2024 seasons.⁵

The age distribution of hospitalizations follows the classic "U-shaped" curve associated with H3N2 dominance:

• Adults ≥ 65 years: 53.4 per 100,000 (Highest burden)

• Children 0-4 years: 21.5 per 100,000

• Adults 50-64 years: 17.5 per 100,000.⁵

This demographic pattern confirms that the burden of severe disease is falling heavily on the elderly, whose immune systems are less capable of mounting a protective response against a drifted H3N2 strain, and on young children who are immunologically naïve.

Clinical Presentation and Pathogenesis

The "Super Flu" Phenomenon: Discourse vs. Reality

The emergence of subclade K has been accompanied by intense media coverage labeling the strain as a "Super Flu".¹⁸ Reports describe patients suffering from unusually severe symptoms, leading to public anxiety regarding the virulence of the variant. While "Super Flu" is not a clinical diagnosis, the term captures the subjective experience of patients facing a drifted H3N2 infection.

Medical experts have clarified that while the variant is highly transmissible, it does not appear to be intrinsically more virulent in terms of infection-fatality ratio (IFR) compared to historical H3N2 strains.⁶ The perception of "super" severity likely stems from the volume of infections; when millions are infected simultaneously, the absolute number of severe cases rises, creating a visibility bias. Furthermore, H3N2 infections are generally more symptomatic than H1N1 or Influenza B infections, leading to a harsher patient experience even in uncomplicated cases.²⁰

Symptomatology and Systemic Inflammation

The clinical syndrome associated with subclade K includes the standard influenza tetrad of fever, cough, headache, and myalgia, but with notable intensity. Clinicians and patients report "deep body aches" affecting the back, legs, and shoulders, distinct from the mild soreness of a common cold.¹⁸

Other reported symptoms include:

• Sudden high fever (>101°F)

• Extreme fatigue and exhaustion

• Persistent, non-productive cough

• Sore throat

• Gastrointestinal Distress: Unusual for seasonal influenza in adults, there are reports of vomiting and diarrhea associated with this variant.¹⁸

• Shortness of breath and chest pain.¹⁸

The intensity of these symptoms, particularly the myalgia and fever, suggests a robust induction of pro-inflammatory cytokines (e.g., interferon, interleukin-6). Because the virus partially evades initial neutralizing antibodies, viral replication may reach higher titers before the cellular immune response engages, leading to a more abrupt and systemic inflammatory cascade—often referred to as a "cytokine storm" in severe cases—which manifests as debilitating body aches.²¹

Secondary Complications and Bacterial Superinfection

A critical, often overlooked aspect of influenza mortality is the role of secondary bacterial infections. Influenza viruses replicate in the epithelial cells of the respiratory tract, causing cytopathic damage that strips away the protective lining of the lungs. This "denuding" of the epithelium creates a permissive environment for opportunistic bacteria to invade.²⁴

In the 2025-2026 season, emergency departments are advised to be vigilant for secondary bacterial pneumonia, particularly caused by Streptococcus pneumoniae or Staphylococcus aureus (including MRSA). This typically presents as a "biphasic" illness: the patient initially improves from the viral flu, only to relapse days later with a return of high fever, productive sputum, and respiratory distress.²² Historical data indicates that secondary bacterial pneumonia is a leading cause of death during pandemics and severe H3N2 seasons.²⁶ The current surge in emergency room visits includes cases of flu-related sepsis, underscoring the lethal potential of these secondary complications.²⁶

Immunology and Vaccination

The Challenge of Strain Selection and Mismatch

The central immunological challenge of the 2025-2026 season is the mismatch between the vaccine strain and the circulating wild-type virus. Influenza vaccines are reformulated annually based on surveillance data from the preceding months. For the 2025-2026 Northern Hemisphere season, the World Health Organization (WHO) selected a reference virus from the subclade J.2 lineage (e.g., A/Thailand/8/2022-like).¹⁷

However, the subclade K variant (J.2.4.1) surged in global prevalence after this selection was finalized, specifically during the late summer months of 2025.⁶ This timing is a structural vulnerability of the current egg-based and cell-based vaccine manufacturing timelines, which require approximately six months to produce sufficient doses. Consequently, the antibodies elicited by the vaccine are "drifted" from the circulating K variant. While they are genetically related, the structural changes at the glycosylation sites (T135K) reduce the binding affinity of vaccine-induced antibodies.²⁷

Vaccine Effectiveness: Real-World Evidence

Despite the antigenic mismatch, empirical data offers a more optimistic picture than laboratory inhibition assays might suggest. Data from the United Kingdom Health Security Agency (UKHSA), which monitored the subclade K wave earlier in the season, provides critical early estimates of Vaccine Effectiveness (VE).

Table 2: Early Estimates of 2025-2026 Influenza Vaccine Effectiveness.⁹

The high effectiveness in children (70-75%) is particularly encouraging. This may be due to the robust immune response in children or the "imprinting" effect where their primary exposures are more closely related to recent H3N2 clades. Conversely, the lower effectiveness in adults (30-40%) is typical for H3N2 seasons. This is often attributed to "immunosenescence" (aging of the immune system) and "original antigenic sin," where the adult immune system preferentially boosts antibodies against historical flu strains encountered in childhood rather than the specific new vaccine strain.⁹

Crucially, experts emphasize that a VE of 30-40% in adults is still epidemiologically valuable. It significantly reduces the severity of illness. Even if a vaccinated individual gets infected (due to the mismatch preventing sterilizing immunity), the vaccine-induced T-cells and non-neutralizing antibodies can limit viral replication, preventing the progression to respiratory failure or death.¹⁰ Thus, the vaccine remains a vital tool for decoupling infection from mortality.

Immunosenescence and Population Immunity

The high susceptibility of the elderly to subclade K is compounded by immunosenescence. As the immune system ages, its ability to generate high-affinity antibodies to novel antigens declines. In H3N2 seasons, this demographic consistently faces the highest risks. The current season's data reinforces this, with hospitalization rates for those over 65 being nearly triple that of the general adult population.¹⁷ This underscores the importance of high-dose or adjuvanted influenza vaccines for seniors, which are designed to overcome this age-related immune deficit, though specific data on their performance against subclade K is still emerging.

Vulnerable Populations and Mortality

Pediatric Impact

Pediatric mortality is a tragic and sensitive indicator of influenza severity. As of Week 51, the CDC has confirmed eight influenza-associated pediatric deaths for the 2025-2026 season.² While this number is lower than the catastrophic peaks of the 2023-2024 season (which saw nearly 200 pediatric deaths), the trajectory is concerning; five of these eight deaths occurred in a single week (Week 51).²

The majority of these deaths are linked to Influenza A viruses. Historical analysis reveals that approximately 90% of pediatric flu deaths occur in children who are not fully vaccinated.¹⁷ This statistic highlights a critical failure in preventative care coverage. The rapid rise in pediatric hospitalizations (21.5 per 100,000 for ages 0-4) further suggests that subclade K is capable of causing severe lower respiratory tract disease in young children.⁵

Geriatric Burden and Long-Term Care

The burden of morbidity is heavily skewed toward older adults. Surveillance from the National Healthcare Safety Network (NHSN) regarding Long-Term Care Facilities (LTCFs) indicates a hospitalization rate of 22.9 per 100,000 residents.⁵ Outbreaks in these closed settings are notoriously difficult to control once the virus is introduced. The H3N2 subtype is particularly efficient at causing "attack rate" outbreaks in nursing homes, often with high case-fatality rates due to the underlying frailty of the resident population. The current data mirrors the severe H3N2 seasons of 2017-2018, warning of a potential spike in excess mortality among the elderly as the season peaks.

Therapeutic Interventions and Management

Antiviral Efficacy

In the context of high viral transmission and vaccine mismatch, antiviral therapeutics become a cornerstone of clinical management. The CDC and global health bodies have confirmed that the circulating subclade K viruses remain susceptible to currently approved neuraminidase inhibitors and polymerase inhibitors.¹⁸

Key antiviral options include:

• Oseltamivir (Tamiflu): The standard of care, taken orally. Effective if started within 48 hours of symptom onset.

• Baloxavir marboxil (Xofluza): A single-dose oral medication that inhibits the cap-dependent endonuclease. It is particularly useful for improving compliance and rapidly reducing viral shedding.¹⁸

• Zanamivir (Relenza): An inhaled powder, useful for patients without underlying airway disease.

• Peramivir (Rapivab): An intravenous option for hospitalized patients or those unable to tolerate oral medications.¹⁸

Genetic analysis has not shown widespread resistance markers in subclade K, meaning these drugs retain their clinical utility.⁶ However, their efficacy is time-dependent. They are most effective at shortening illness duration and preventing complications when administered within 48 hours of symptom onset. Given the rapid progression of symptoms reported with this variant ("Super Flu"), early access to testing and antivirals is critical for high-risk patients.

Clinical Care Guidelines

For the 2025-2026 season, clinical guidelines emphasize a low threshold for treating high-risk patients (elderly, pregnant, immunocompromised, young children) with suspected influenza, even before laboratory confirmation is returned.² Due to the high pre-test probability of influenza during this surge, empiric treatment is recommended to prevent the window of efficacy from closing. Furthermore, clinicians are advised to monitor for signs of secondary bacterial pneumonia (recurrence of fever, dyspnea) and initiate appropriate antibiotic therapy if superinfection is suspected.²²

Conclusion

The 2025-2026 influenza season serves as a potent reminder of the influenza virus's capacity for rapid evolution and epidemiological disruption. The emergence of the H3N2 subclade K (J.2.4.1) variant has driven a vertical surge in infections, outpacing recent seasons and straining healthcare capacity across the United States. While the media narrative of a "Super Flu" captures the intensity of the patient experience—marked by severe myalgia and systemic inflammation—clinical data suggests that the virus operates within the known bounds of H3N2 severity, albeit at a very high volume.

The partial antigenic mismatch caused by the T135K and K189R mutations has reduced the sterilizing immunity provided by the vaccine, yet real-world evidence confirms that vaccination continues to offer substantial protection against hospitalization, particularly for children. The disparity in vaccine effectiveness between age groups (70% in children vs. 30% in adults) highlights the ongoing challenge of immunosenescence and the need for next-generation vaccine technologies.

As the season progresses through early 2026, the public health priority must remain on mitigating the impact on the most vulnerable. This involves maximizing vaccine uptake to utilize the remaining protection against severe disease, ensuring rapid access to antivirals, and maintaining vigilance against secondary bacterial complications. The 2025-2026 season is not a pandemic event, but a severe seasonal epidemic that demands a coordinated and robust medical response.

Works cited

1. Weekly US Influenza Surveillance Report: Key Updates for Week 50, ending December 13, 2025 | FluView, accessed January 3, 2026, https://www.cdc.gov/fluview/surveillance/2025-week-50.html

2. Weekly US Influenza Surveillance Report: Key Updates for Week 51, ending December 20, 2025 | FluView, accessed January 3, 2026, https://www.cdc.gov/fluview/surveillance/2025-week-51.html

3. Flu Watch for 1/1/2026 and Outbreak Update-3–It’s BAD!, accessed January 3, 2026, https://www.peoplespharmacy.com/articles/flu-watch-for-1-1-2026-and-outbreak-update-3-its-bad

4. Extended influenza seasons in Australia and New Zealand in 2025 due to the emergence of influenza A(H3N2) subclade K viruses - PMC - NIH, accessed January 3, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12701333/

5. US Influenza Activity Accelerates Into the New Year as Hospitalizations Rise, accessed January 3, 2026, https://www.contagionlive.com/view/us-influenza-activity-accelerates-into-the-new-year-as-hospitalizations-rise

6. With an absent CDC and mismatched 'subclade K' flu strain, experts face upcoming season with uncertainty | CIDRAP, accessed January 3, 2026, https://www.cidrap.umn.edu/influenza-vaccines/absent-cdc-and-mismatched-subclade-k-flu-strain-experts-face-upcoming-season

7. “Superflu” or same old flu? How subclade K influenza is playing out worldwide, accessed January 3, 2026, https://www.gavi.org/vaccineswork/superflu-or-same-old-flu-how-subclade-k-influenza-playing-out-worldwide

8. Indonesian MPs urge swift action as H3N2 subcladeK spreads, accessed January 3, 2026, https://en.antaranews.com/news/398116/indonesian-mps-urge-swift-action-as-h3n2-subcladek-spreads

9. Early influenza virus characterisation and vaccine effectiveness in England in autumn 2025, a period dominated by influenza A(H3N2) subclade K - NIH, accessed January 3, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12639273/

10. Subclade K Flu Strain Explained and How to Stay Protected - Priority Care Clinics, accessed January 3, 2026, https://prioritycareclinics.com/subclade-k-flu-strain/

11. US flu activity takes big jump as 2 deaths in kids confirmed, accessed January 3, 2026, https://www.cidrap.umn.edu/influenza-general/us-flu-activity-takes-big-jump-2-deaths-kids-confirmed

12. Assessing the risk of influenza for the EU/EEA in the context of increasing circulation of A(H3N2) subclade K - ECDC, accessed January 3, 2026, https://www.ecdc.europa.eu/sites/default/files/documents/Threat%20Assessment%20Brief%20-%20Assessing%20the%20risk%20of%20increasing%20circulation%20of%20A%28H3N2%29%20subclade%20K.pdf

13. Evolution of Influenza A(H3N2) Viruses in 2 Consecutive Seasons of Genomic Surveillance, 2021–2023 - Oxford Academic, accessed January 3, 2026, https://academic.oup.com/ofid/article/10/12/ofad577/7424824

14. Past Weekly Report | FluView - CDC, accessed January 3, 2026, https://www.cdc.gov/fluview/surveillance/past-reports.html

15. Georgia flu-associated deaths tick up in most recent report with possibility for another surge, accessed January 3, 2026, https://www.gpb.org/news/2026/01/02/georgia-flu-associated-deaths-tick-in-most-recent-report-possibility-for-another

16. Flu is rising rapidly, driven by a new variant. Here's what to know, accessed January 3, 2026, https://www.kare11.com/article/syndication/associatedpress/flu-is-rising-rapidly-driven-by-a-new-variant-heres-what-to-know/616-a0c7613f-0edf-47e3-8b3b-38df78f9b3dc

17. Influenza Activity in the United States during the 2024–25 Season and Composition of the 2025–26 Influenza Vaccine - CDC, accessed January 3, 2026, https://www.cdc.gov/flu/whats-new/2025-2026-influenza-activity.html

18. Super flu cases are rising: Know more about the H3N2 variant, accessed January 3, 2026, https://www.indiatoday.in/health/story/super-flu-h3n2-variant-spreads-in-us-severe-symptoms-vaccine-rising-hospitalisation-2843292-2025-12-29

19. What is the ‘Super Flu’ Subclade K Spreading Across the US & Europe?, accessed January 3, 2026, https://sundayguardianlive.com/world/what-is-the-super-flu-subclade-k-spreading-across-the-us-europe-163122/

20. The ominous new ‘K’ flu variant is spreading as flu shot rates fall, accessed January 3, 2026, https://www.uchealth.org/today/k-flu-variant-spreads-as-flu-shot-rates-fall/

21. US faces worst winters, mutated H3N2 flu strain spreading fast: Early symptoms to know, accessed January 3, 2026, https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/us-faces-worst-winters-mutated-h3n2-flu-strain-spreading-fast-early-symptoms-to-know/articleshow/126252445.cms

22. The New H3N2 "Super Flu" Strain: Will Your Flu Shot Protect You?, accessed January 3, 2026, https://health.stonybrookmedicine.edu/the-new-h3n2-flu-strain-will-your-flu-shot-protect-you/

23. Heads up: huge influenza A wave in Ontario right now - Reddit, accessed January 3, 2026, https://www.reddit.com/r/ontario/comments/1pq7pv0/heads_up_huge_influenza_a_wave_in_ontario_right/

24. Influenza Mediated ER Stress and Secondary Bacterial Infections - NIH RePORTER, accessed January 3, 2026, https://reporter.nih.gov/project-details/10901165

25. Influenza - Washington State Department of Health, accessed January 3, 2026, https://doh.wa.gov/sites/default/files/2025-10/420-002-epitrends2025-10.pdf

26. Winter Viral Surge in 2025: Sick Season is Hitting Hard | LifeFlow, accessed January 3, 2026, https://410medical.com/2025/01/22/winter-viral-surge-in-2025-sick-season-is-hitting-hard/

27. Everything you need to know about 'subclade K' flu - and vaccine protection against it, accessed January 3, 2026, https://www.gavi.org/vaccineswork/everything-you-need-know-about-subclade-k-flu-and-vaccine-protection-against-it

28. How Bad Will This Winter Be for Flu, COVID, RSV, and Measles?, accessed January 3, 2026, https://publichealth.jhu.edu/2025/virus-transmission-trends-winter-2025-26

29. Flu vaccine providing important protection despite new subclade - GOV.UK, accessed January 3, 2026, https://www.gov.uk/government/news/flu-vaccine-providing-important-protection-despite-new-subclade